XML 81 R71.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 15,962 | $ 14,959 | $ 45,485 | $ 45,453
Increase in hedge revenue |  |  | 173 | 533
Revenue related to the sale of the marketing rights |  |  | 118 | 156
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,715 | 7,322 | 21,393 | 20,927
Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,247 | 7,637 | 24,092 | 24,526
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15,663 | 14,334 | 44,789 | 44,146
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,615 | 7,095 | 21,258 | 20,544
Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,048 | 7,239 | 23,531 | 23,601
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 299 | 625 | 696 | 1,307
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 227 | 135 | 383
Corporate, Non-Segment | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 199 | 398 | 561 | 925
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,263 | 12,963 | 40,442 | 39,826
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,153 | 6,620 | 19,840 | 19,119
Pharmaceutical | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,110 | 6,343 | 20,602 | 20,707
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,338 | 5,426 | 18,403 | 15,487
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,795 | 3,331 | 11,142 | 9,307
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,543 | 2,095 | 7,261 | 6,180
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 299 | 284 | 884 | 825
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 144 | 439 | 427
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 146 | 140 | 445 | 397
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 260 | 202 | 734 | 660
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 160 | 142 | 476 | 426
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 60 | 258 | 235
Pharmaceutical | Operating Segments | Welireg |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 38 | 146 | 83
Pharmaceutical | Operating Segments | Welireg | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 51 | 38 | 141 | 83
Pharmaceutical | Operating Segments | Welireg | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 0 | 6 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenue from collaborative arrangement | 52 | 39 | 142 | 124
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 32 | 108 | 87
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10 | 7 | 33 | 37
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,585 | 2,294 | 7,015 | 5,428
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 838 | 957 | 1,718 | 1,803
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,746 | 1,337 | 5,297 | 3,624
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 713 | 668 | 1,823 | 1,716
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 567 | 532 | 1,435 | 1,337
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 146 | 136 | 388 | 379
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 156 | 256 | 584 | 644
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 108 | 154 | 381 | 427
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 102 | 203 | 218
Pharmaceutical | Operating Segments | Vaxneuvance |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 214 | 16 | 488 | 32
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 182 | 15 | 423 | 31
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 33 | 1 | 65 | 1
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 140 | 131 | 327 | 457
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 68 | 105 | 280
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 63 | 223 | 177
Pharmaceutical | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 69 | 64 | 151 | 134
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 32 | 27 | 91 | 72
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 37 | 36 | 60 | 62
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 424 | 423 | 1,413 | 1,244
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 265 | 233 | 841 | 665
Pharmaceutical | Operating Segments | Bridion | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 159 | 190 | 572 | 579
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 157 | 114 | 430 | 310
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 49 | 186 | 136
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 87 | 64 | 244 | 174
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 74 | 77 | 215 | 196
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 69 | 72 | 199 | 184
Pharmaceutical | Operating Segments | Dificid | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5 | 6 | 16 | 12
Pharmaceutical | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 63 | 174 | 185
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 2 | 1
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 63 | 173 | 185
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 51 | 62 | 167 | 180
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 13 | 29 | 39
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 47 | 49 | 138 | 141
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 43 | 157 | 120
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 29 | 24 | 86 | 64
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 19 | 71 | 55
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 88 | 259 | 258
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 85 | 249 | 244
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (4) | 3 | 10 | 14
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 57 | 189 | 181
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 57 | 189 | 181
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 640 | 436 | 1,236 | 4,859
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 1,523
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 640 | 436 | 1,236 | 3,336
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 119 | 161 | 377 | 466
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 58 | 68 | 165 | 196
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 61 | 93 | 212 | 270
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 58 | 62 | 176 | 199
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 23 | 20 | 60 | 60
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 35 | 42 | 117 | 139
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 179 | 173 | 539 | 540
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 179 | 173 | 539 | 540
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 49 | 144 | 163
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 49 | 144 | 163
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 581 | 717 | 1,642 | 2,252
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 328 | 332 | 842 | 958
Pharmaceutical | Operating Segments | Januvia | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 252 | 385 | 800 | 1,294
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 255 | 417 | 937 | 1,347
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 90 | 182 | 258
Pharmaceutical | Operating Segments | Janumet | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 211 | 327 | 755 | 1,089
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 549 | 603 | 1,690 | 1,736
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 197 | 194 | 540 | 511
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 353 | 410 | 1,147 | 1,225
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,400 | 1,371 | 4,347 | 4,320
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 462 | 475 | 1,418 | 1,425
Animal Health | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 938 | 896 | 2,929 | 2,894
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 874 | 829 | 2,530 | 2,486
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 205 | 186 | 543 | 521
Animal Health | Operating Segments | Livestock | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 669 | 643 | 1,987 | 1,965
Animal Health | Operating Segments | Companion Animal |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 526 | 542 | 1,817 | 1,834
Animal Health | Operating Segments | Companion Animal | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 257 | 289 | 875 | 904
Animal Health | Operating Segments | Companion Animal | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 269 | $ 253 | $ 942 | $ 929

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |